Get the Stockscreener App
1.13
2.59%
-0.03
Aptevo Therapeutics Inc stock is traded at $1.13, with a volume of 624.97K.
It is down -2.59% in the last 24 hours and down -23.65% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$1.16
Open:
$1.11
24h Volume:
624.97K
Relative Volume:
0.11
Market Cap:
$19.04M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0116
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-16.30%
1M Performance:
-23.65%
6M Performance:
-76.36%
1Y Performance:
-99.00%
1-Day Range:
$1.10
$1.15
1-Week Range:
$1.07
$1.3698
52-Week Range:
$1.04
$118.98
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.13 | 19.55M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics Inc. (APVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aptevo Therapeutics Inc AP81 Stock Analysis and ForecastHealthcare Stock Analysis & High Return Trading Strategies - earlytimes.in
Volume Report: Is Aptevo Therapeutics Inc stock supported by strong fundamentalsShare Buyback & Accurate Intraday Trading Signals - moha.gov.vn
Prepare Yourself for Liftoff: Aptevo Therapeutics Inc (APVO) - setenews.com
Aptevo Therapeutics Announces Promising RAINIER Trial Results - TipRanks
Aptevo’s AML therapy shows strong safety profile in phase 1b/2 trial - Investing.com
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - ACCESS Newswire
Aptevo Therapeutics (NASDAQ: APVO) shows 100% CRS-free safety, 87% CR/CRi in AML - Stock Titan
Aptevo Therapeutics Inc Stock Analysis and ForecastVolatility Index Analysis & Daily Tips From Top Market Analysts - earlytimes.in
Aug Intraday: How analysts rate Aptevo Therapeutics Inc stock today2025 Earnings Surprises & Stock Timing and Entry Methods - moha.gov.vn
EBIT per share of Aptevo Therapeutics, Inc. – MUN:AP81 - TradingView
Targets Report: How Nevis Brands Inc 8DZ stock behaves under inflation pressureRate Hike & Daily Profit Maximizing Trade Tips - BỘ NỘI VỤ
Is Aptevo Therapeutics Inc (APVO) positioned for future growth? - Setenews
How Aptevo Therapeutics Inc. (AP81) stock behaves under inflation pressureJuly 2025 Pullbacks & Low Drawdown Investment Strategies - Newser
Aptevo Therapeutics (APVO) Stock Analysis Report | Financials & Insights - Benzinga
Is Aptevo Therapeutics Inc a good long term investmentDividend Growth Stocks & Low Entry Risk Stocks - earlytimes.in
Bombay Cycle Motor Agency Limited Recovery Hinges on Volume BreakoutCurrency Fluctuation Impact & Trusted Financial Advisors at No Cost - earlytimes.in
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
[EFFECT] Aptevo Therapeutics Inc. SEC Filing - Stock Titan
There is no way Aptevo Therapeutics Inc (APVO) can keep these numbers up - Setenews
[424B4] Aptevo Therapeutics Inc. Prospectus Filed Pursuant to Rule 424(b)(4) - Stock Titan
Aptevo Therapeutics reports Q3 EPS ($2.23) vs. ($357.86) last year - MSN
D pipelineMarket Trend Report & Risk Adjusted Buy/Sell Alerts - newser.com
Will Aptevo Therapeutics Inc. stock benefit from AI adoption2025 Pullback Review & Low Risk Growth Stock Ideas - newser.com
How Aptevo Therapeutics Inc. stock reacts to oil pricesAnalyst Upgrade & Advanced Swing Trade Entry Plans - newser.com
What macro factors could drive Aptevo Therapeutics Inc. (AP81) stock higherJuly 2025 Snapshot & Consistent Income Trade Recommendations - newser.com
Why Aptevo Therapeutics Inc. stock remains a top recommendationEarnings Recap Summary & High Conviction Buy Zone Alerts - newser.com
Can Aptevo Therapeutics Inc. (AP81) stock sustain breakout momentumWeekly Market Outlook & Accurate Intraday Trade Tips - newser.com
Why ETFs are accumulating Aptevo Therapeutics Inc. (AP81) stockTake Profit & Risk Adjusted Buy and Sell Alerts - newser.com
Combining machine learning predictions for Aptevo Therapeutics Inc.2025 Investor Takeaways & Weekly High Return Stock Opportunities - newser.com
Aptevo Therapeutics Inc. stock chart pattern explainedTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):